{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2013"],"condition":["Neoplasm Metastasis","Metastatic Disease","Colorectal Neoplasms","Cáncer Colorrectal Metastásico","Metastatic colorectal cancer","Colorectal cancer stage IV"],"disease":["Metastatic Colorectal Cancer","Colorectal Cancer Stage Iv","Neoplasm Metastasis","Metastatic Disease","Colorectal Neoplasms","Cáncer Colorrectal Metastásico"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2146473"],"location":["Spain"],"study_start_month":["6"],"keyword":["Regorafenib","Frail and unfit patient","Metastatic colorectal cancer"],"repository":["ECRIN MDR"],"study_status":["Completed"],"additional_accession":[]},"is_claimable":false,"name":"Regorafenib in Frail and/or Unfit for Chemotherapy Patients With Metastatic Colorectal Cancer","description":"The purpose of this study is to assess the efficacy and safety of single-agent regorafenib in the first line treatment of frail and/or unfit for polychemotherapy patients with metastatic colorectal cancer (mCRC)","dates":{"creation":"2013-06-15"},"accession":"2146473","cross_references":{"ClinicalTrials___gov":["NCT01875380"],"EU Clinical Trials Register":["2013-000236-94"]}}